Aquestive Therapeutics, Inc. (AQST) Financial Statements
Aquestive Therapeutics, Inc. (AQST) reported trailing twelve-month revenue of $54.1M (up 22.6% year on year) and net income of -$78.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$45.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AQSTAquestive Therapeutics, Inc.Follow AQST — free
—
Price chart with a free account
- Market cap
- 502.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.4 | 52.6 | 45.8 | 50.8 | 47.7 | 50.6 | 57.6 | 44.5 | 54.1 | |
| Gross profit | — | — | 32.9 | — | 28.3 | 29.8 | 39.7 | 26.0 | 36.3 | |
| Research & development | 23.1 | 20.6 | 19.9 | 17.0 | 17.5 | 13.1 | 20.3 | 17.2 | 15.9 | |
| Operating income | -48.9 | -52.7 | -42.9 | -34.7 | -42.1 | -15.1 | -30.8 | -71.1 | -52.7 | |
| Pre-tax income | -61.4 | -66.2 | -55.8 | -70.5 | -54.4 | -7.6 | -44.2 | -83.8 | -78.2 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | -0.0 | 0.0 | 0.0 | |
| Net income | -61.4 | -66.2 | -55.8 | -70.5 | -54.4 | -7.9 | -44.1 | -83.8 | -78.2 | |
| Diluted EPS ($) | -2.96 | -2.61 | -1.66 | -1.85 | -1.12 | -0.13 | -0.51 | -0.78 | -0.62 | |
| Diluted shares (mn) | — | — | — | 38.1 | 48.7 | 61.3 | 86.7 | 106.9 | — |
USD millions · SEC XBRL
Aquestive Therapeutics, Inc. — questions
- What is Aquestive Therapeutics, Inc.'s revenue?
- $54.1M over the twelve months to 2026-06-30, up 22.6% year on year, from its 10-Q and 10-K filings.
- What is Aquestive Therapeutics, Inc.'s net income?
- -$78.2M over the twelve months to 2026-06-30.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- -$45.9M over the twelve months to 2026-06-30.
- What are Aquestive Therapeutics, Inc.'s diluted earnings per share?
- $-0.62 over the twelve months to 2026-06-30.
Every figure on this page comes from Aquestive Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.